Stock Scorer

Century Therapeutics, Inc. (IPSC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 40M 80M 120M Q1 '22: 1.1M Q2 '22: 1.4M Q3 '22: 2.2M Q4 '22: 521K Q1 '23: 1.7M Q2 '23: 99K Q3 '23: 148K Q4 '23: 268K Q1 '24: 855K Q2 '24: 771K Q3 '24: 791K Q4 '24: 4.2M Q1 '25: 109.2M Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '22 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Income Quarterly

-60M -30M 0 30M 60M 90M Q3 '21: -25.8M Q4 '21: -28M Q1 '22: -37.4M Q2 '22: -31.4M Q3 '22: -31.7M Q4 '22: -33.3M Q1 '23: -32.1M Q2 '23: -35.1M Q3 '23: -35.6M Q4 '23: -43.8M Q1 '24: -31.3M Q2 '24: -34.8M Q3 '24: -34.8M Q4 '24: -37.3M Q1 '25: 74.2M Q2 '25: -34.7M Q3 '25: -36.1M Q4 '25: -20.7M Q1 '26: -23.7M Q2 '26: -36.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -30M 0 30M 60M 90M Q3 '21: -26M Q4 '21: -28.2M Q1 '22: -37.5M Q2 '22: -31M Q3 '22: -30.7M Q4 '22: -31.7M Q1 '23: -31.3M Q2 '23: -33.3M Q3 '23: -32.7M Q4 '23: -39.4M Q1 '24: -28.1M Q2 '24: -31.2M Q3 '24: -31.2M Q4 '24: -36.1M Q1 '25: 76.6M Q2 '25: -32.5M Q3 '25: -34.4M Q4 '25: -19.2M Q1 '26: -21.6M Q2 '26: -34.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -30M 0 30M 60M 90M Q3 '21: -24M Q4 '21: -24.4M Q1 '22: 86.8M Q2 '22: -25.6M Q3 '22: -24.2M Q4 '22: -22.9M Q1 '23: -29.2M Q2 '23: -19.2M Q3 '23: -13.6M Q4 '23: -26.2M Q1 '24: -30.2M Q2 '24: -27.3M Q3 '24: -28.3M Q4 '24: -24.2M Q1 '25: -34.6M Q2 '25: -27.6M Q3 '25: -25.6M Q4 '25: -16.1M Q1 '26: -25.3M Q2 '26: -19.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -30M 0 30M 60M 90M Q4 '20: -15.1M Q1 '21: -24.1M Q2 '21: -29.1M Q3 '21: -39.7M Q4 '21: -41.1M Q1 '22: 82.7M Q2 '22: -36M Q3 '22: -34M Q4 '22: -29.2M Q1 '23: -34.2M Q2 '23: -23.8M Q3 '23: -16.9M Q4 '23: -27.2M Q1 '24: -30.8M Q2 '24: -27.6M Q1 '25: -35.1M Q2 '25: -27.9M Q3 '25: -25.8M Q1 '26: -25.8M Q2 '26: -20.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '20: 7.5M Q3 '20: 7.5M Q1 '21: 7.7M Q2 '21: 12M Q3 '21: 54.5M Q1 '22: 57.1M Q2 '22: 57.7M Q3 '22: 58M Q1 '23: 58.6M Q2 '23: 59.3M Q3 '23: 59.4M Q1 '24: 62.3M Q2 '24: 82.1M Q3 '24: 84.7M Q1 '25: 86.1M Q2 '25: 86.2M Q3 '25: 86.5M Q1 '26: 193.5M Q2 '26: 205.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '21: -6.88 Q4 '21: -2.96 Q1 '22: -1.23 Q2 '22: 0.16 Q3 '22: 0.11 Q4 '22: -2.97 Q1 '23: -2.84 Q2 '23: -2.86 Q3 '23: -2.88 Q4 '23: -2.29 Q1 '24: -2.21 Q2 '24: -2.03 Q3 '24: -1.85 Q4 '24: -1.63 Q1 '25: -0.29 Q2 '25: -0.29 Q3 '25: -0.32 Q4 '25: -0.14 Q1 '26: -1.14 Q2 '26: -0.93 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for IPSC: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.